ATLAS-2m
This page contains details about ViiV Healthcare clinical trials. Approved prescribing information must continue to guide appropriate use of ViiV Healthcare medicines. This information may vary from country to country. Before prescribing any product mentioned in this section, Healthcare Professionals should consult prescribing information approved in their country.
STUDY DESCRIPTION
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of long-acting (LA) cabotegravir ▼ (CAB) + rilpivirine ▼ (RPV) LA administered every 8 weeks (Q8W) compared to CAB LA + RPV LA administered every 4 weeks (Q4W) over a 48-week treatment period in approximately 1020 adult HIV-1 infected subjects. Subjects will be divided in 2 groups; Group 1 will include subjects receiving current anti-retroviral (ART) standard of care (SOC) therapy whereas group 2 will include subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in both groups will be randomized to receive CAB LA + RPV LA Q4W or Q8W. The study will be carried out in 3 phases including screening phase, maintenance phase and extension phase. Subjects choosing not to enter the Extension phase can complete their study participation at the Week 100 visit and enter into the 52-week Long-Term Follow-Up (LTFU) Phase as required.
Discover more about the ATLAS-2M study and access relevant reference information on the ViiV clinical study register
NP-GBL-HVX-WCNT-220013 April 2022
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
